Do analysts prefer TLSA or ZYBT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, TLSA or ZYBT?

Zhengye Biotechnology has higher revenue and earnings than Tiziana Life Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tiziana Life Sciences N/A N/A -$18.43M N/A N/A Zhengye Biotechnology $16.64M 6.81 -$9.98M N/A N/A

Is TLSA or ZYBT more profitable?

Company Net Margins Return on Equity Return on Assets Tiziana Life Sciences N/A N/A N/A Zhengye Biotechnology N/A N/A N/A

Does the media prefer TLSA or ZYBT?

In the previous week, Zhengye Biotechnology had 46 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 48 mentions for Zhengye Biotechnology and 2 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 1.05 beat Zhengye Biotechnology's score of 0.06 indicating that Tiziana Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tiziana Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zhengye Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 46 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ZYBT or UNCY?

Unicycive Therapeutics has a consensus price target of $21.75, suggesting a potential upside of 299.45%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Unicycive Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has preferable valuation and earnings, ZYBT or UNCY?

Zhengye Biotechnology has higher revenue and earnings than Unicycive Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 6.81 -$9.98M N/A N/A Unicycive Therapeutics $680K 219.32 -$26.56M -$2.21 N/A

Is ZYBT or UNCY more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Zhengye Biotechnology N/A N/A N/A Unicycive Therapeutics N/A -134.69% -84.51%

Does the media favor ZYBT or UNCY?

In the previous week, Zhengye Biotechnology had 46 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 48 mentions for Zhengye Biotechnology and 2 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.34 beat Zhengye Biotechnology's score of 0.06 indicating that Unicycive Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zhengye Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 46 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Unicycive Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer NGEN or ZYBT?

NervGen Pharma presently has a consensus target price of $14.00, indicating a potential upside of 689.18%. Given NervGen Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe NervGen Pharma is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NervGen Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.83 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, NGEN or ZYBT?

NervGen Pharma has higher earnings, but lower revenue than Zhengye Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NervGen Pharma N/A N/A N/A -$0.09 N/A Zhengye Biotechnology $16.64M 6.81 -$9.98M N/A N/A

Is NGEN or ZYBT more profitable?

Company Net Margins Return on Equity Return on Assets NervGen Pharma N/A N/A N/A Zhengye Biotechnology N/A N/A N/A

Does the media favor NGEN or ZYBT?

In the previous week, Zhengye Biotechnology had 36 more articles in the media than NervGen Pharma. MarketBeat recorded 48 mentions for Zhengye Biotechnology and 12 mentions for NervGen Pharma. Zhengye Biotechnology's average media sentiment score of 0.06 beat NervGen Pharma's score of -0.24 indicating that Zhengye Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NervGen Pharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zhengye Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 46 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ZYBT or GNLX?

Genelux has a consensus price target of $18.00, indicating a potential upside of 515.38%. Given Genelux's stronger consensus rating and higher possible upside, analysts clearly believe Genelux is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Genelux 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger valuation and earnings, ZYBT or GNLX?

Zhengye Biotechnology has higher revenue and earnings than Genelux. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 6.81 -$9.98M N/A N/A Genelux $10K 13,115.70 -$32.15M -$0.85 N/A

Is ZYBT or GNLX more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Zhengye Biotechnology N/A N/A N/A Genelux N/A -174.55% -123.65%

Do analysts recommend ZYBT or VTVT?

vTv Therapeutics has a consensus target price of $56.67, suggesting a potential upside of 70.97%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe vTv Therapeutics is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 vTv Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Which has higher earnings & valuation, ZYBT or VTVT?

Zhengye Biotechnology has higher revenue and earnings than vTv Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 6.81 -$9.98M N/A N/A vTv Therapeutics $1.02M 128.03 -$26.97M -$0.93 N/A

Is ZYBT or VTVT more profitable?

vTv Therapeutics' return on equity of 3.96% beat Zhengye Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Zhengye Biotechnology N/A N/A N/A vTv Therapeutics N/A 3.96% 2.86%

Does the media favor ZYBT or VTVT?

In the previous week, Zhengye Biotechnology had 45 more articles in the media than vTv Therapeutics. MarketBeat recorded 48 mentions for Zhengye Biotechnology and 3 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.67 beat Zhengye Biotechnology's score of 0.06 indicating that vTv Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zhengye Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 46 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral vTv Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Trading of Zhengye Biotechnology was halted at 10:29 AM EST due to "LULD Pause".

Zhengye Biotechnology (ZYBT) Competitors

$2.39 -5.62 (-70.16%)

As of 01:43 PM Eastern

Compare

ZYBT vs. TLSA, UNCY, NGEN, GNLX, and VTVT

Should you buy Zhengye Biotechnology stock or one of its competitors? MarketBeat compares Zhengye Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zhengye Biotechnology include Tiziana Life Sciences (TLSA), Unicycive Therapeutics (UNCY), NervGen Pharma (NGEN), Genelux (GNLX), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical products" industry.

How does Zhengye Biotechnology compare to Tiziana Life Sciences?

Tiziana Life Sciences (NASDAQ:TLSA) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Zhengye Biotechnology	N/A	N/A	N/A

Tiziana Life Sciences has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.18, indicating that its share price is 318% less volatile than the broader market.

In the previous week, Zhengye Biotechnology had 46 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 48 mentions for Zhengye Biotechnology and 2 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 1.05 beat Zhengye Biotechnology's score of 0.06 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tiziana Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zhengye Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	46 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zhengye Biotechnology has higher revenue and earnings than Tiziana Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
Zhengye Biotechnology	$16.64M	6.81	-$9.98M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Tiziana Life Sciences and Zhengye Biotechnology tied by winning 3 of the 6 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Unicycive Therapeutics?

Zhengye Biotechnology (NASDAQ:ZYBT) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Zhengye Biotechnology's return on equity of 0.00% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Unicycive Therapeutics	N/A	-134.69%	-84.51%

Zhengye Biotechnology has a beta of -2.18, meaning that its stock price is 318% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

Unicycive Therapeutics has a consensus price target of $21.75, suggesting a potential upside of 299.45%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Zhengye Biotechnology had 46 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 48 mentions for Zhengye Biotechnology and 2 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.34 beat Zhengye Biotechnology's score of 0.06 indicating that Unicycive Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zhengye Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	46 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Unicycive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

40.4% of Unicycive Therapeutics shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Zhengye Biotechnology has higher revenue and earnings than Unicycive Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	6.81	-$9.98M	N/A	N/A
Unicycive Therapeutics	$680K	219.32	-$26.56M	-$2.21	N/A

Summary

Unicycive Therapeutics beats Zhengye Biotechnology on 8 of the 13 factors compared between the two stocks.

How does Zhengye Biotechnology compare to NervGen Pharma?

NervGen Pharma (NASDAQ:NGEN) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

NervGen Pharma has higher earnings, but lower revenue than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	N/A	-$0.09	N/A
Zhengye Biotechnology	$16.64M	6.81	-$9.98M	N/A	N/A

NervGen Pharma presently has a consensus target price of $14.00, indicating a potential upside of 689.18%. Given NervGen Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe NervGen Pharma is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	N/A	N/A
Zhengye Biotechnology	N/A	N/A	N/A

In the previous week, Zhengye Biotechnology had 36 more articles in the media than NervGen Pharma. MarketBeat recorded 48 mentions for Zhengye Biotechnology and 12 mentions for NervGen Pharma. Zhengye Biotechnology's average media sentiment score of 0.06 beat NervGen Pharma's score of -0.24 indicating that Zhengye Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NervGen Pharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zhengye Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	46 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

NervGen Pharma beats Zhengye Biotechnology on 4 of the 7 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Genelux?

Zhengye Biotechnology (NASDAQ:ZYBT) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Zhengye Biotechnology's return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Genelux	N/A	-174.55%	-123.65%

Zhengye Biotechnology has higher revenue and earnings than Genelux.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	6.81	-$9.98M	N/A	N/A
Genelux	$10K	13,115.70	-$32.15M	-$0.85	N/A

37.3% of Genelux shares are owned by institutional investors. 7.5% of Genelux shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Zhengye Biotechnology had 48 more articles in the media than Genelux. MarketBeat recorded 48 mentions for Zhengye Biotechnology and 0 mentions for Genelux. Zhengye Biotechnology's average media sentiment score of 0.06 beat Genelux's score of 0.00 indicating that Zhengye Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Zhengye Biotechnology	Neutral
Genelux	Neutral

Genelux has a consensus price target of $18.00, indicating a potential upside of 515.38%. Given Genelux's stronger consensus rating and higher possible upside, analysts clearly believe Genelux is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Zhengye Biotechnology has a beta of -2.18, indicating that its stock price is 318% less volatile than the broader market. Comparatively, Genelux has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market.

Summary

Genelux beats Zhengye Biotechnology on 7 of the 13 factors compared between the two stocks.

How does Zhengye Biotechnology compare to vTv Therapeutics?

Zhengye Biotechnology (NASDAQ:ZYBT) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

vTv Therapeutics has a consensus target price of $56.67, suggesting a potential upside of 70.97%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe vTv Therapeutics is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

17.5% of vTv Therapeutics shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Zhengye Biotechnology had 45 more articles in the media than vTv Therapeutics. MarketBeat recorded 48 mentions for Zhengye Biotechnology and 3 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.67 beat Zhengye Biotechnology's score of 0.06 indicating that vTv Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zhengye Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	46 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
vTv Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

vTv Therapeutics' return on equity of 3.96% beat Zhengye Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
vTv Therapeutics	N/A	3.96%	2.86%

Zhengye Biotechnology has higher revenue and earnings than vTv Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	6.81	-$9.98M	N/A	N/A
vTv Therapeutics	$1.02M	128.03	-$26.97M	-$0.93	N/A

Zhengye Biotechnology has a beta of -2.18, indicating that its stock price is 318% less volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

Summary

vTv Therapeutics beats Zhengye Biotechnology on 10 of the 13 factors compared between the two stocks.

Get Zhengye Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZYBT vs. The Competition

Export

Metric	Zhengye Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$113.26M	$3.65B	$6.80B	$12.43B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	N/A	20.62	27.03	24.19
Price / Sales	6.81	311.45	515.69	92.93
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	2.57	8.13	10.67	6.24
Net Income	-$9.98M	$23.81M	$3.59B	$331.42M
7 Day Performance	236.38%	-1.31%	-0.60%	-1.18%
1 Month Performance	218.67%	2.40%	1.63%	-1.34%
1 Year Performance	-58.00%	44.89%	25.09%	18.73%

Zhengye Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZYBT Zhengye Biotechnology	1.0409 of 5 stars	$2.39 -70.2%	N/A	+40.8%	$113.26M	$16.64M	N/A	278	Trending News Gap Down Trading Halted High Trading Volume
TLSA Tiziana Life Sciences	0.7486 of 5 stars	$1.10 -0.9%	N/A	-34.5%	$141.26M	N/A	N/A	8	Positive News Gap Up
UNCY Unicycive Therapeutics	3.1186 of 5 stars	$5.05 +0.6%	$21.75 +330.7%	+23.0%	$137.51M	$680K	N/A	9
NGEN NervGen Pharma	2.2249 of 5 stars	$1.67 -1.2%	$14.00 +738.3%	N/A	$134.65M	N/A	N/A	N/A	News Coverage Analyst Upgrade High Trading Volume
GNLX Genelux	2.1949 of 5 stars	$2.82 -3.1%	$18.00 +538.3%	-12.0%	$130.49M	$10K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZYBT) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zhengye Biotechnology (ZYBT) Competitors

ZYBT vs. TLSA, UNCY, NGEN, GNLX, and VTVT

How does Zhengye Biotechnology compare to Tiziana Life Sciences?

Summary

How does Zhengye Biotechnology compare to Unicycive Therapeutics?

Summary

How does Zhengye Biotechnology compare to NervGen Pharma?

Summary

How does Zhengye Biotechnology compare to Genelux?

Summary

How does Zhengye Biotechnology compare to vTv Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT vs. The Competition

Zhengye Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zhengye Biotechnology (ZYBT) Competitors

ZYBT vs. TLSA, UNCY, NGEN, GNLX, and VTVT

How does Zhengye Biotechnology compare to Tiziana Life Sciences?

Is TLSA or ZYBT more profitable?

Which has more volatility and risk, TLSA or ZYBT?

Does the media prefer TLSA or ZYBT?

Which has better earnings and valuation, TLSA or ZYBT?

Do analysts prefer TLSA or ZYBT?

Summary

How does Zhengye Biotechnology compare to Unicycive Therapeutics?

Is ZYBT or UNCY more profitable?

Which has more volatility and risk, ZYBT or UNCY?

Do analysts prefer ZYBT or UNCY?

Does the media favor ZYBT or UNCY?

Do institutionals & insiders have more ownership in ZYBT or UNCY?

Which has preferable valuation and earnings, ZYBT or UNCY?

Summary

How does Zhengye Biotechnology compare to NervGen Pharma?

Which has higher earnings & valuation, NGEN or ZYBT?

Do analysts prefer NGEN or ZYBT?

Is NGEN or ZYBT more profitable?

Does the media favor NGEN or ZYBT?

Summary

How does Zhengye Biotechnology compare to Genelux?

Is ZYBT or GNLX more profitable?

Which has stronger valuation and earnings, ZYBT or GNLX?

Do institutionals & insiders believe in ZYBT or GNLX?

Does the media prefer ZYBT or GNLX?

Do analysts rate ZYBT or GNLX?

Which has more risk & volatility, ZYBT or GNLX?

Summary

How does Zhengye Biotechnology compare to vTv Therapeutics?

Do analysts recommend ZYBT or VTVT?

Do insiders & institutionals believe in ZYBT or VTVT?

Does the media favor ZYBT or VTVT?

Is ZYBT or VTVT more profitable?

Which has higher earnings & valuation, ZYBT or VTVT?

Which has more risk and volatility, ZYBT or VTVT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT vs. The Competition

Zhengye Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools